COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Graham, C. N. [1 ]
Hechmati, G. [2 ]
Hjelmgren, J. [2 ]
De Liege, F. [3 ]
Lanier, J. [3 ]
Knoof, A. [3 ]
Knox, H. [1 ]
Barber, B. [4 ]
de Pouvourville, G. [5 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen France SAS, Neuilly Sur Seine, France
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] ESSEC Business Sch, Cergy Pontoise, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：A632 / A632
页数：1
相关论文
共 50 条
  • [21] Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial
    Emi, Y.
    Yamanaka, T.
    Muro, K.
    Uetake, H.
    Oki, E.
    Takahashi, T.
    Katayose, Y.
    Yoshida, K.
    Sakamoto, M.
    Aishima, S.
    Ishida, K.
    Imura, J.
    Unno, M.
    Hyodo, I.
    Tomita, N.
    Sugihara, K.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
    Heinrich, Kathrin
    Heinemann, Volker
    Westphalen, Benedikt
    Oecal, Osman
    Van Hazel, Guy A.
    Gibbs, Peter
    Seidensticker, Max
    Ricke, Jens
    Seidensticker, Ricarda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer
    Bayoglu, Ibrahim Vedat
    Yildiz, Ibrahim
    Varol, Umut
    Cokmert, Suna
    Kucukzeybek, Yuksel
    Alacacioglu, Ahmet
    Demir, Lutfiye
    Dirican, Ahmet
    Akyol, Murat
    Yildiz, Yasar
    Tarhan, Mustafa Oktay
    JOURNAL OF BUON, 2015, 20 (02): : 460 - 467
  • [24] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
    Schwartzberg, Lee S.
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Hecht, J. Randolph
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +
  • [25] TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
    Borelli, Beatrice
    Moretto, Roberto
    Lonardi, Sara
    Bonetti, Andrea
    Antoniotti, Carlotta
    Pietrantonio, Filippo
    Masi, Gianluca
    Burgio, Valentina
    Marmorino, Federica
    Salvatore, Lisa
    Rossini, Daniele
    Zaniboni, Alberto
    Zucchelli, Gemma
    Martignetti, Angelo
    Di Battista, Monica
    Pella, Nicoletta
    Passardi, Alessandro
    Boccaccino, Alessandra
    Leone, Francesco
    Colombo, Camilla
    Granetto, Cristina
    Vannini, Francesca
    Marsico, Valentina Angela
    Martinelli, Erika
    Antonuzzo, Lorenzo
    Vitello, Stefano
    Delliponti, Laura
    Boni, Luca
    Cremolini, Chiara
    Falcone, Alfredo
    ESMO OPEN, 2018, 3 (04)
  • [26] A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 ns first-line treatment for metastatic colorectal cancer (mCRC); Interim results.
    Hecht, J. R.
    Yoshio, T.
    Mitchell, E. P.
    Dees, M. S., III
    Countouriotis, A. M.
    Maneval, E. C.
    Kretzschmar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)
    van Hazel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059
  • [28] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
    Van Cutsem, E.
    Prenen, H.
    Guillen-Ponce, C.
    Bennouna, J.
    Di Benedetto, M.
    Bouche, O.
    Staines, H.
    Oum'Hamed, Z.
    Studeny, M.
    Capdevila, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
  • [29] mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale
    Nagata, Naoki
    Mishima, Hideyuki
    Kurosawa, Shuichi
    Oba, Koji
    Sakamoto, Junichi
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 154 - +
  • [30] Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
    Takahashi, Takao
    Ishida, Kazuyuki
    Emi, Yasunori
    Sakamoto, Michiie
    Imura, Johji
    Aishima, Shinichi
    Muro, Kei
    Uetake, Hiroyuki
    Oki, Eiji
    Katayose, Yu
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    CANCERS, 2022, 14 (18)
12345